# US 2026/0234683 A1 · Manufacture of messenger rna with kp34 polymerase

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0234683 A1
- Document ID: US20260234683A1
- Status: Published application
- Kind: A1
- Application number: 19/160,680
- Filed: 2024-03-07
- Published: 2026-08-13
- Earliest claimed: 2023-03-07
- Assignees: Sanofi Pasteur Limited
- Applicants: Sanofi Pasteur Inc.
- Inventors: Jianping CUI; Yaroslav MOROZOV
- Web page: https://patentgrep.com/patent/US20260234683A1

## CPC

- C12P 19/34: Polynucleotides, e.g. nucleic acids, oligoribonucleotides
- C12N 9/1247: {DNA-directed RNA polymerase (2.7.7.6)}
- C12Y 207/07006: DNA-directed RNA polymerase (2.7.7.6)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present disclosure provides methods and compositions for improving the in vitro transcription (IVT) of messenger RNA using Klebsiella phage KP34 RNA polymerase. In particular, the present disclosure provides a method for manufacturing messenger RNA comprising: (a) providing a DNA template comprising a nucleic acid sequence encoding an mRNA transcript for expression of a polypeptide or protein; (b) contacting the DNA template with a Klebsiella phage KP34 RNA polymerase under conditions suitable for IVT of the mRNA transcript.

## Claims

### Claim 1

A method for manufacturing messenger RNA (mRNA) comprising:
a. providing a DNA template comprising a nucleic acid sequence encoding an mRNA transcript for expression of a polypeptide or protein;
b. contacting the DNA template with a Klebsiella phage KP34 RNA polymerase under conditions suitable for in vitro transcription (IVT) of the mRNA transcript.

### Claim 2 (depends on 1)

The method of claim 1, wherein the Klebsiella phage KP34 RNA polymerase provided in step (b) is recombinantly expressed in Escherichia coli cells and purified to remove enzymatically inactive aggregates.

### Claim 3 (depends on 2)

The method of claim 2, wherein enzymatically inactive aggregates are removed from an affinity-purified preparation comprising the Klebsiella phage KP34 RNA polymerase.

### Claim 4 (depends on 3)

The method of claim 3, wherein the enzymatically inactive aggregates are removed by size exclusion chromatography e.g., gel filtration.

### Claim 5

The method of any one of the preceding claims, wherein the Klebsiella phage KP34 RNA polymerase comprises less than 5% enzymatically inactive aggregates.

### Claim 6

The method of any one of the preceding claims, wherein the amino acid sequence of the Klebsiella phage KP34 RNA polymerase is at least 90% identical (e.g., at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical, or identical) to the amino acid sequence of SEQ ID NO: 1.

### Claim 7

The method of any one of the preceding claims, wherein the Klebsiella phage KP34 RNA polymerase is present at a concentration ranging from 0.01-0.5 mg/mL.

### Claim 8

The method of any one of the preceding claims, wherein the mRNA transcript comprises at least 500 ribonucleotides.

### Claim 9

The method of any one of the preceding claims, wherein the amount of double-stranded RNA (dsRNA) comprised in the mRNA transcripts obtained in step (b) is below the limit of detection.

### Claim 10 (depends on 9)

The method of claim 9, wherein the presence of dsRNA is determined by dot blot using antibody J2.

### Claim 11

The method of any one of the preceding claims, wherein the amount of dsRNA generated in step (b) is at least 10-fold lower relative to a corresponding method using SP6 RNA polymerase or T7 RNA polymerase in place of the Klebsiella phage KP34 RNA polymerase.

### Claim 12

The method of any one of the preceding claims, wherein the mRNA transcripts obtained in step (b) comprise less than 1% of dsRNA by weight.

### Claim 13 (depends on 12)

The method of claim 12, wherein the amount of dsRNA is determined by ELISA using antibodies J2 and K1.

### Claim 14

The method of any one of the preceding claims, wherein 10% by weight or less of the mRNA transcripts obtained in step (b) comprise non-templated nucleic acids.

### Claim 15

The method of any one of the preceding claims, wherein less than 10% by weight of the mRNA transcripts obtained in step (b) are abortive transcripts.

### Claim 16 (depends on 15)

The method of claim 15, wherein the abortive transcripts comprise less than 20 nucleotides.

### Claim 17 (depends on 15, 16)

The method of claim 15 or 16, wherein the abortive transcripts are detectable by gel electrophoresis.

### Claim 18

The method of any one of the preceding claims, wherein the method comprises synthesizing at least 100 mg of mRNA in a single batch.

### Claim 19

The method of any one of the preceding claims, wherein the DNA template comprises a Klebsiella phage KP34 promoter sequence operably linked to the nucleic acid sequence encoding the mRNA transcript.

### Claim 20 (depends on 19)

The method of claim 19, wherein the promoter sequence comprises the nucleic acid sequence set forth in SEQ ID NO: 5.

### Claim 21 (depends on 19, 20)

The method of claim 19 or 20, wherein the promoter sequence is optimized to improve mRNA transcript yield.

### Claim 22 (depends on 19, 20, 21)

The method of any one of claims 19-21, wherein the yield of the mRNA transcripts obtained in step (b) is comparable to the yield achieved with a corresponding method using SP6 RNA polymerase or T7 RNA polymerase in place of the Klebsiella phage KP34 RNA polymerase.

### Claim 23 (depends on 21, 22)

The method of claim 21 or 22, wherein the promoter sequence comprises the nucleic acid sequence set forth in SEQ ID NO: 7, 8, 9, or 41.

### Claim 24 (depends on 21, 22)

The method of claim 21 or 22, wherein the promoter sequence comprises the nucleic acid sequence set forth in SEQ ID NO: 26, 32, or 35, e.g., SEQ ID NO: 26.

### Claim 25

The method of any one of the preceding claims, wherein the DNA template is at a concentration of 0.05 mg/mL to 0.5 mg/mL.

### Claim 26

The method of any one of the preceding claims, wherein the DNA template is linear or linearized.

### Claim 27

The method of any one of the preceding claims, wherein IVT takes place in the presence of magnesium chloride (MgCl2).

### Claim 28 (depends on 27)

The method of claim 27, wherein the MgCl2 concentration is greater than 20 mM.

### Claim 29 (depends on 28)

The method of claim 28, wherein the MgCl2 concentration is about 25 mM.

### Claim 30

The method of any one of the preceding claims, wherein IVT takes place in the presence of sodium chloride (NaCl).

### Claim 31 (depends on 30)

The method of claim 30, wherein the NaCl concentration is less than 20 mM.

### Claim 32 (depends on 31)

The method of claim 31, wherein the NaCl concentration is about 0.5 mM.

### Claim 33

The method of any one of the preceding claims, wherein IVT takes place in the presence of buffering agent.

### Claim 34 (depends on 33)

The method of claim 33, wherein the buffering agent is selected from Tris, HEPES, ammonium sulfate, sodium bicarbonate, sodium citrate, sodium acetate, potassium phosphate, and sodium phosphate.

### Claim 35 (depends on 34)

The method of claim 34, wherein the buffering agent is Tris-HCl.

### Claim 36 (depends on 35)

The method of claim 35, wherein Tris-HCl is present at a concentration of less than 40 mM.

### Claim 37 (depends on 36)

The method of claim 36, wherein Tris-HCl is present at a concentration of about 25 mM.

### Claim 38

The method of any one of the preceding claims, wherein IVT takes place in the presence of unmodified ribonucleotides.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The method of any one of claims 1-38, wherein IVT takes place in the presence of a modified ribonucleotide.

### Claim 40 (depends on 39)

The method of claim 39, wherein the modified ribonucleotide has a modified nucleoside.

### Claim 41 (depends on 40)

The method of claim 40, wherein the modified nucleoside is selected from 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, 5-methylcytidine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, 5-methylcytidine, 5-methoxyuridine 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine, pseudouridine, N1-methylpseudouridine, 2-thiouridine, and 2-thiocytidine.

### Claim 42 (depends on 41)

The method of claim 41, wherein the modified nucleoside is pseudouridine, N1-methylpseudouridine, 5-methylcytidine, or 5-methoxyuridine, e.g., wherein the modified nucleoside is N1-methylpseudouridine.

### Claim 43

The method of any one of the preceding claims, wherein IVT takes place in the presence of ribonucleotides, wherein each ribonucleotide is present at a concentration of 0.1 mM to 10 mM.

### Claim 44

The method of any one of the preceding claims, wherein IVT takes place at a pH of 7.0 to 7.7.

### Claim 45 (depends on 44)

The method of claim 44, wherein the pH is about 7.5.

### Claim 46

The method of any one of the preceding claims, wherein IVT takes place at a temperature of 37° C. to 42° C.

### Claim 47 (depends on 46)

The method of claim 46, wherein the temperature is 37° C.

### Claim 48

The method of any one of the preceding claims, wherein IVT takes place over a period of 30 minutes to 6 hours.

### Claim 49

The method of any one of the preceding claims, wherein IVT is terminated by addition of DNase I and a DNase I buffer.

### Claim 50

The method of any one of the preceding claims, further comprising a step of purifying the mRNA transcripts obtained in step (b) from the KP34 RNA polymerase.

### Claim 51 (depends on 50)

The method of claim 50, wherein the step of purifying the mRNA transcripts involves a method other than (i) cellulose chromatography, and/or (ii) high-performance chromatography (HPLC) with a buffer system comprising triethylammonium acetate and/or acetonitrile.

### Claim 52

A composition comprising mRNA transcripts and Klebsiella phage KP34 RNA polymerase, wherein the composition comprises less than 1% of dsRNA by weight and wherein less than 10% of the mRNA transcripts by weight are abortive transcripts.

### Claim 53 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 52)

The composition of claim 52, wherein said composition is obtainable by the method of any one of claims 1-49.

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

An mRNA obtained by the method of any one of claims 1-51.

### Claim 55 (depends on 54)

A pharmaceutical composition comprising the mRNA of claim 54.

### Claim 56 (depends on 55)

A method of treating or preventing a disease or disorder in a subject, said method comprising administering the pharmaceutical composition of claim 55 to the subject.
